Pharmaceutical News
-
Moderna’s ASCO presentations highlight personalized cancer vaccine and multiple myeloma programs
Moderna announced the acceptance of three abstracts related to its mRNA-based oncology programs for the 2026 ASCO Annual Meeting. Key highlights include updates on the Phase IIb KEYNOTE-942 study of intismeran autogene in melanoma and a Phase I/II study of mRNA-2808 for multiple myeloma, emphasizing personalized cancer vaccine development. Read more
-
Lilly’s Selpercatinib Cuts Lung Cancer Recurrence by 83% in Study
Eli Lilly’s Retevmo (selpercatinib) significantly reduced disease recurrence or death by 83% in early-stage RET fusion-positive non-small cell lung cancer, according to the Phase III LIBRETTO-432 study. With a 92% event-free survival rate at 24 months, this marks a major advancement in targeted adjuvant treatment options for these patients. Read more
-
Roche obesity pipeline advances as petrelintide and enicepatide enter Phase III
By VETTAPHARMA reporter – Derek Roche: Roche reported new clinical data highlighting progress across its obesity pipeline, with investigational candidates petrelintide and enicepatide advancing into Phase III development as the company expands its presence in the rapidly growing weight-management market. The update includes late-breaking findings from the Phase II ZUPREME-1 trial evaluating petrelintide, an investigational human amylin analog for weight management in people living with overweight and obesity. Roche said the data demonstrated favorable efficacy and safety outcomes, supporting continued development of the asset as both a standalone treatment and a potential combination therapy. Roche also highlighted new data from… Read more
-
Pluvicto Strengthens Case for Earlier Use in Advanced Prostate Cancer
Novartis’ Pluvicto showed consistent efficacy in treating metastatic hormone-sensitive prostate cancer (mHSPC) in the Phase III PSMAddition study. Combining Pluvicto with standard therapies reduced the risk of disease progression and PSA progression. These results may support earlier use of Pluvicto, potentially expanding its patient base and improving outcomes. Read more
-
Novartis to Showcase Immunology Advances at EULAR 2026 Congress
Novartis will present 31 abstracts at the 2026 EULAR Congress, showcasing its advancements in immunology for complex autoimmune diseases. Key presentations include findings on Cosentyx for polymyalgia rheumatica and data on ianalumab for Sjögren’s disease and lupus. Their diverse portfolio targets significant unmet medical needs in treatment options. Read more
-
FDA Grants Priority Review for Zydus’s Saroglitazar in Primary Biliary Cholangitis Treatment
Zydus Therapeutics has received priority review from the FDA for its New Drug Application of saroglitazar, intended for treating primary biliary cholangitis (PBC). The Phase IIb/III EPICS-III trial showed significant efficacy, with 56.7% of patients responding positively. A decision is expected by November 27, 2026, potentially enhancing treatment options for PBC. Read more
-
Daiichi Sankyo ASCO oncology updates strengthen ADC portfolio expansion across multiple cancers
Daiichi Sankyo plans to present over 25 oncology abstracts at the 2026 ASCO Annual Meeting, showcasing clinical data from major trials on Enhertu and Datroway. The presentations cover various cancers, highlighting recent approvals and advancing new therapies, including next-generation antibody-drug conjugates and innovative investigational medicines for challenging cancer types. Read more
-
CVS restores Zepbound coverage as Lilly expands obesity market access significantly
CVS Caremark will restore coverage for Eli Lilly’s obesity injection Zepbound and add oral therapy Foundayo, reversing a previous preference for Novo Nordisk’s Wegovy. This decision, effective June 1 and October 1 respectively, aims to enhance patient access, affordability, and competition in the obesity treatment market, benefiting approximately 90 million members. Read more
-
FDA Approves AstraZeneca’s Imfinzi for High-Risk NMIBC: Key Insights
The FDA has approved Imfinzi (durvalumab) alongside Bacillus Calmette-Guérin (BCG) for adult patients with high-risk non-muscle-invasive bladder cancer. Results from the POTOMAC trial indicated significant improvement in disease-free survival compared to BCG alone. This approval enhances treatment options and aims to improve outcomes for patients at risk of disease progression. Read more
-
WHO Prioritizes Maftivimab for Bundibugyo Ebola Trials
Regeneron Pharmaceuticals’ maftivimab has been prioritized by the WHO for clinical trials to treat the Bundibugyo strain of Ebola virus disease amid an ongoing outbreak in the Democratic Republic of the Congo. This comes as no approved treatments exist for this strain, emphasizing an urgent need for effective therapeutic options and further research. Read more
-
GSK’s Bepirovirsen Achieves Unprecedented Cure Rates in HBV Patients
GSK’s bepirovirsen showed unprecedented functional cure rates in chronic hepatitis B patients, achieving 27% success at Week 72 in the Phase IIb B-Clear trial. Compared to 0% in the control group, the trial suggests potential for finite-duration therapy over lifelong treatment. Bepirovirsen could enhance GSK’s competitive edge in hepatitis B treatments. Read more
-
Global pharma leaders urge Japan investment reforms amid life sciences competitiveness concerns
Executives from multinational pharmaceutical companies met with Japanese Prime Minister Shigeru Ishiba to promote policies for enhancing life sciences investment and biopharmaceutical innovation in Japan. The focus was on creating a supportive environment for research, faster innovation adoption, and improved access to medicines, amid growing competitive pressures in the global market. Read more